The gap-map: what CBG has been tested for, and what it hasn't.
Across 10 tracked conditions, CBG has 0 with established or demonstrated human efficacy, 1 with any human data at all, and 1 with no primary evidence. The rest are preclinical or mechanistic only. This is the honest state of the evidence.
Every grade below comes from the studies in our evidence registry. Mechanism only means a receptor interaction has been measured but no study has tested an effect. Preclinical only means animal or lab evidence with no human data. Early human data means a small or short trial exists and the claim is still graded Low. No primary evidence means our registry has no study supporting a CBG effect there. None of these statuses describes a benefit, and none of this is medical advice.
This map covers CBG only. CBDV, CBGa, CBGV, CBC, CBN and THCV each have their own monograph, and their conditions are not tracked here yet. That reflects the reach of the map; their evidence is a separate question. CBDV makes the point: it has a completed randomised controlled trial that missed its primary endpoint. This map does not show it; you will find it on the CBDV monograph.
Ten conditions, five kinds of study.
Each cell counts the registry studies linked to that condition’s claim, by study type. A study that points the other way is counted on its own, in oxblood. The chip beside each name is the claim’s grade; open a row for what the next rung would take.
| Condition | Human | Animal | In vitro | Biochemistry | Review | Next rung |
|---|---|---|---|---|---|---|
| Anxiety & stressgrade: Low | 1 | 0 for, 2 against | 0 | 0 | 0 | |
, for Anxiety & stress | ||||||
| Antibacterial (MRSA)grade: Lowpreclinical only | 0 | 1 | 1 | 0 | 0 | |
, for Antibacterial (MRSA) | ||||||
| Appetite stimulationgrade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 | |
, for Appetite stimulation | ||||||
| Colorectal cancer (preclinical)grade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 | |
, for Colorectal cancer (preclinical) | ||||||
| Inflammatory bowel disease (colitis)grade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 | |
, for Inflammatory bowel disease (colitis) | ||||||
| Neuroinflammationgrade: Lowpreclinical only | 0 | 0 | 1 | 0 | 0 | |
, for Neuroinflammation | ||||||
| Neuroprotection (Huntington's disease)grade: Lowpreclinical only | 0 | 1 | 0 | 0 | 0 | |
, for Neuroprotection (Huntington's disease) | ||||||
| Blood pressure / cardiovasculargrade: Hypothesized | 0 | 0 | 1 | 0 | 0 | |
, for Blood pressure / cardiovascular | ||||||
| Skinevidence state: Mechanism only | not linked in the data | not linked in the data | not linked in the data | not linked in the data | not linked in the data | |
, for Skin | ||||||
| Intraocular pressure (glaucoma)evidence state: No primary evidence | 0 | 0 | 0 | 0 | 0 | |
, for Intraocular pressure (glaucoma) | ||||||
The matrix counts linked registry studies only: 9 of 10 rows carry a claim with a study linkage in our data; a row shown “—” has none, which is a fact about the linkage and not about the literature. A row’s grade may sit at or below what its studies would allow, never above it.
Brain & nervous system.
Anxiety & stress
grade: Low1 small, short (acute, single-dose) human trial (graded Low). Contradicting evidence in our registry: 2 preclinical animal studies. Animal studies do not consistently reproduce an anxiety-reducing effect — one found no effect and another reported an anxiety-increasing effect — so the preclinical picture is mixed and does not confirm a benefit. Reaching 'Demonstrated' would take, on top of what we already hold: one larger, controlled, non-acute human trial — or two independent human observational studies. No amount of further animal or laboratory work can raise it — only human data can.
, for Anxiety & stress
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: two animal (preclinical) effect studies from independent research groups, agreeing in direction — or one human trial of any size — including a small, short (acute / single-dose) one.
, for Neuroinflammation
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
, for Neuroprotection (Huntington's disease)
Cardiovascular.
Blood pressure / cardiovascular
grade: HypothesizedA receptor mechanism is measured, but no study has measured an actual effect here. Reaching 'Low' would take, on top of what we already hold: one in-vitro / laboratory effect study — or one animal (preclinical) effect study from a research group not already counted here.
, for Blood pressure / cardiovascular
Digestive.
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
, for Appetite stimulation
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
, for Colorectal cancer (preclinical)
Evidence is 1 preclinical study (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
, for Inflammatory bowel disease (colitis)
Eyes.
Intraocular pressure (glaucoma)
evidence state: No primary evidenceOften attributed to CBG, but our verified registry holds NO primary study supporting it — and none arguing against it either. We hold no primary study either way, so the honest state is UNKNOWN, not disproven. Putting this on the evidence ladder at all (grade 'Low') would take: one in-vitro / laboratory effect study — or one animal (preclinical) effect study from a research group not already counted here.
, for Intraocular pressure (glaucoma)
Immune & inflammatory.
Evidence is 2 preclinical studies (animal / lab) — no human data. Reaching 'Emerging' would take, on top of what we already hold: one animal (preclinical) effect study from a research group not already counted here — or one human trial of any size — including a small, short (acute / single-dose) one.
, for Antibacterial (MRSA)
Skin.
Skin
evidence state: Mechanism onlyOnly a proposed receptor mechanism in the knowledge graph — our registry holds no graded claim and no study of any kind here, so no effect has been measured. Putting this on the evidence ladder at all (grade 'Low') would take: one in-vitro / laboratory effect study — or one animal (preclinical) effect study from a research group not already counted here.
, for Skin
A gap is not a promise.
Read the map as an inventory. It records what has been studied, what has not, and what would need to happen before a grade could move. Nothing on it says CBG works for any of these conditions. Catalogue in progress.
The cardiovascular entry above is mechanistic and safety-relevant, not a benefit claim. CBG shows potent α2-adrenoceptor agonism in vitro, and α2 agonists can lower blood pressure — but no study has measured an actual blood-pressure effect of CBG. If you take blood-pressure medication or have a cardiovascular condition, consult a clinician first.
The map is generated straight from our evidence registry with every grade untouched, and the empty rows stay in plain view. Gap-map built 2026-08-23. Every underlying study sits in the Research Library.